Overview

Latiglutenase as a Treatment for Celiac Disease

Status:
Completed
Trial end date:
2021-01-22
Target enrollment:
Participant gender:
Summary
Single Center, Randomized, Double-Blind, Placebo Controlled, Gluten Challenge Trial in Patients with Well-Controlled Celiac Disease
Phase:
Phase 2
Details
Lead Sponsor:
Immunogenics, LLC
Collaborators:
National Center for Complementary and Integrative Health (NCCIH)
National Institutes of Health (NIH)